Skip to search formSkip to main contentSkip to account menu

alisporivir

Known as: MeAla(3)EtVal(4)-cyclosporin 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Cyclosporine
DEBIO-025

Narrower (1)

UNIL025

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Adaptive Mutations in Replicase Transmembrane Subunits Can Counteract Inhibition of Equine Arteritis Virus RNA Synthesis by Cyclophilin Inhibitors
Currently, no approved treatments are available to combat infections with nidoviruses, a group of positive-stranded RNA viruses… 
2014
2014
O9 BOTH CYCLOPHILIN INHIBITORS AND DIRECT-ACTING ANTIVIRALS PREVENT PKR ACTIVATION IN HCV-INFECTED CELLS
2013
2013
Correlation of Naturally Occurring HIV-1 Resistance to DEB025 with Capsid Amino Acid Polymorphisms
DEB025 (alisporivir) is a synthetic cyclosporine with inhibitory activity against human immunodeficiency virus type-1 (HIV-1) and… 
2013
2013
821 INTERFERON (IFN)-FREE ALISPORIVIR (ALV) HAS A BETTER OVERALL SAFETY PROFILE COMPARED TO IFN-CONTAINING TREATMENT: A POOLED ANALYSIS OF THE ALV DEVELOPMENT PROGRAM
2012
2012
Update on alisporivir in treatment of viral hepatitis C
Introduction: There are two classes of anti-hepatitis C virus (HCV) agents currently in development: direct-acting antivirals… 
2012
2012
1405 ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY
2012
2012
1406 ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH…
2012
2012
506 ALISPORIVIR-INDUCED INHIBITION OF CELLULAR CYCLOPHILINS DISRUPTS HEPATITIS B VIRUS (HBV) REPLICATION IN VITRO AND IS SYNERGISTIC IN COMBINATION WITH DIRECT ANTIVIRAL TARGETING HBV-DNA POLYMERASE
Review
2011
Review
2011
Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.
Most novel drugs directed against the hepatitis C virus (HCV) including the recently approved NS3/4A protease inhibitors… 
2011
2011
1105 LONG-TERM FOLLOW-UP OF OCCULT HBV QUASISPECIES DIVERSITY AND LYMPHOTROPISM IN HIV-1-INFECTED PATIENTS REACTIVE FOR ANTIBODY TO HBV CORE ANTIGEN (ANTI-HBC)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)